Skip to main content
. 2020 Feb 7;24(5):2736–2748. doi: 10.1111/jcmm.15028

Table 2.

Discussed natural agonists of PPARγ (from 2010 to 2019)

Functions Agonists Years References
Anti‐cancer Chromolaena odorata, Luteolin, Stereoisomers ginsenosides 2012 136, 137, 138, 139, 140
Turbinaria ornata and Padina pavonica 2015 141
Resveratrol 2016, 2019 42, 95, 113, 115
Anti‐fibrosis Puerarin 2013, 2017 74
Piperine 2017 143
Berberine 2018 144
Anti‐inflammation Monascin 2011, 2014 145, 146, 147
Astaxanthin, Ankaflavin, Biochanin A, Cullin‐3, Danhong, Daidzein 2012 148, 149, 150, 151, 152, 153
Ursolic acid, Epigallocatechin gallate, Monascin 2013 154, 155, 156
Rhizoma Dioscoreae Nipponicae polysaccharides, Harpagoside, Tectorigenin, Chrysin 2015 157, 158, 159, 160
Huangkui, Tripchlorolide, Kochia scoparia and Rosa multiflora, Resveratrol, Chrysin, Daidzein 2016 115, 121, 161, 162, 163, 164
Astragalus, Fraglide‐1, Madecassic acid, Epigallocatechin Gallate, Hesperetin 2017 66
Isoprenylated flavonoid, chrysogenum J08NF‐4, Portulaca oleracea L., Betulin, Terminalia arjuna, Naringin 2018 69, 169, 170, 171, 172, 173
Beta‐caryophyllene, Wogonin, Resveratrol, Hesperetin 2019 113, 174, 175, 176
Metabolism regulation Cerco‐A, Mycophenolic acid, Fructus Schisandrae, Monascin 2011 156, 177, 178, 179
Ankaflavin, Astaxanthin, Danhong 2012 149, 150, 152
Amorfrutin, Honokiol, Monascin 2013 156, 180, 181
Chebulagic acid, Monascin 2014 145, 147, 182
Kaempferol, Lonicera japonica Thunb, Quercetin, Tectorigenin 2015 160, 183, 184
Osthole, Isorhamnetin, Huangkui, Saponins and sapogenins, Resveratrol, quercetin 2016 95, 162, 185, 186, 187, 188
ZINC13408172, 4292805, 44179 and 901461, Lycium, Astragalus, Tetrahydrocannabinolic acid, Astragaloside IV 2017 168, 189, 190, 191, 192
Betulin, Chlorogenic acid, Isoprenylated flavonoid, Gentiopicroside, Geranylgeraniol, Moringa concanensis Nimmo, Terminalia arjuna, Saponins and sapogenins 2018 169, 170, 172, 193, 194, 195, 196
Kaempferia parviflora, Moringa concanensis Nimmo, Resveratrol 2019 42, 95, 197, 198
HHS Vulnerability Disclosure